BioMarin Pharma (BMRN) Appoints Mark Alles to its Board

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to its Board of Directors effective January 1, 2022.

"We are thrilled to have Mark join BioMarin's Board of Directors. He is a renowned leader in the biopharmaceutical industry, bringing deep operational, financial, business development and commercial experience to our exceptional board," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin. "I look forward to the many significant contributions Mark will make as we drive the consistent introduction of innovative and transformational products for patients."

"I am honored to serve on the Board of Directors of BioMarin, a company that shares my dedication to continued biomedical innovation that can be translated into breakthrough therapies," said Mr. Alles. "I am excited to be part of an organization focused on accelerating drug discovery and development, product approvals, and successful commercial launches focused on delivering transformational therapeutic options to address unmet medical needs."

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
• Alamo Group executive to retire, move to consulting role
• Inuvo CFO to retire; Derric Ciccone named president and CFO